Impact of remote location on quality care delivery and relationships to adverse health outcomes in patients with diabetes and chronic kidney disease.

Search TravelDoctorOnline

Authors: Bello AK,Hemmelgarn B,Lin M,Manns B,Klarenbach S,Thompson S,James M,Tonelli M,Alberta Kidney Disease Network,
Address: Department of Medicine and Public Health Sciences, University of Alberta, Edmonton, AB, Canada.
Journal: Nephrol Dial Transplant.


Publication: 2012 Oct;27(10):3849-55. doi: 10.1093/ndt/gfs267. Epub 2012 Jul 2.

abstract

BACKGROUND:

To investigate the relation of residence location, markers of good quality healthcare and adverse clinical outcomes in patients with diabetes and chronic kidney disease (CKD).

METHODS:

We identified 31 337 individuals with diabetes and estimated glomerular filtration rate (eGFR) 15-59 mL/min/1.73 m(2) from a population-based cohort (n= 1 278 375) of adults with serum creatinine measured at least once during 2005 or 2006 in Alberta, Canada. The study population was classified into categories based on travel distance by road from residence location to the closest nephrologist: (0-50, 50.1-100, 100.1-200 and >200 km).

RESULTS:

At follow-up, compared with those living within 50 km, remote dwellers were less likely to visit a nephrologist, less likely to have hemoglobin A1c and urinary albumin measured within 1 year of the index eGFR, and less likely to receive an angiotensin converting enzyme inhibitor, angiotensin receptor blocker or statin (all P < 0.0001). In adjusted models, compared with those with CKD (Stage 3 or 4) living within 50 km, the adjusted likelihood of all-cause hospitalization was [1.4 (95% confidence interval, CI, 1.3-1.6)], [1.3 (95% CI, 1.1-1.6)] and [1.3 (95% CI, 1.2-1.5)]-fold higher for patients living 50.1-100, 100.1-200 and >200 km away from a nephrologist, respectively (P < 0.0001). The hazard ratio of all-cause mortality increased with increasing distance: [1.07 (95% CI, 0.9-1.2)], [1.1 (95% CI, 0.9-1.2)] and [1.2 (95% CI, 1.0-1.4)], respectively (P < 0.0001).

CONCLUSIONS:

Compared with those living closer to a nephrologist, remote dwellers with diabetes and CKD were less likely to receive recommended quality care, and more likely to experience adverse health outcomes.



Related Articles
Quality of care and mortality are worse in chronic kidney disease patients living in remote areas.
Kidney Int. 2011
Quality of care and mortality are worse in chronic kidney disease patients living in remote areas.
Rucker D, Hemmelgarn BR, Lin M, Manns BJ, Klarenbach SW, Ayyalasomayajula B, James MT, Bello A, Gordon D, Jindal KK, et al. Kidney Int. 2011 Jan; 79(2):210-7. Epub 2010 Oct 6.
Review Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Health Technol Assess. 2010
Review Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, et al. Health Technol Assess. 2010 Apr; 14(21):1-184.
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.
Arch Intern Med. 2011
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.
Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M, et al. Arch Intern Med. 2011 Nov 28; 171(21):1920-7.
Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada.
Am J Kidney Dis. 2007
Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada.
Curtis BM, Barrett BJ, Djurdjev O, Singer J, Levin A. Am J Kidney Dis. 2007 Nov; 50(5):733-42.
Review Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cochrane Database Syst Rev. 2011
Review Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Cochrane Database Syst Rev. 2011 Oct 5; (10):CD007751. Epub 2011 Oct 5.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.